EUCTR2007-003784-42-DE
Active, not recruiting
Not Applicable
Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation - Revlimid as Maintenance in MM
niversity Medical Center Hamburg-Eppendorf0 sitesSeptember 4, 2008
ConditionsMultiple Myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago)MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myeloma
DrugsRevlimid
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Multiple Myeloma patients who received allogeneic stem cell transplantation (100 to 180 days ago)
- Sponsor
- niversity Medical Center Hamburg-Eppendorf
- Status
- Active, not recruiting
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Understand and voluntarily sign an informed consent form
- •2\. Age \>18 years at the time of signing the informed consent form
- •3\. Able to adhere to the study visit schedule and other protocol requirements
- •4\. Multiple myeloma patients who received allogeneic stem cell transplantation (100
- •to 180 days ago)
- •5\. No active acute GvHD (grade II – IV)
- •6\. No active infectious complications
- •7\. ECOG performance status of \< 2 at study entry
- •8\. Laboratory test results within these ranges:
- •Absolute WBC count \>3\.0 x 10^9/l
Exclusion Criteria
- •1\. Any serious medical condition, laboratory abnormality, or psychiatric illness that
- •would prevent the subject from signing the informed consent form
- •2\. Pregnant or breast feeding females. (Lactating females must agree not to breast
- •feed while taking lenalidomide)
- •3\. Use of any other experimental drug or therapy within 28 days of baseline
- •4\. Known hypersensitivity to thalidomide
- •5\. Concurrent use of other anti\-cancer agents or treatments
- •6\. Known positive for HIV or infectious hepatitis, type A, B, or C
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Dose-finding of Lenalidomide as Maintenance in Multiple MyelomaMultiple MyelomaNCT00778752Universitätsklinikum Hamburg-Eppendorf24
Completed
Phase 1
Evaluation of the Feasible dose of Lenalidomide as maintenance therapy after Allogeneic hematopoietic stem cell Transplantation for multiple myelomamultiple myeloma (including plasma cell leukemia)JPRN-UMIN000010470Division of Hematology, Saitama Medical Center, Jichi Medical University9
Active, not recruiting
Phase 1
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant - MM-ALLO-06-07_BISPatients With Newly Diagnosed Multiple MyelomaMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2008-004529-41-ITFONDAZIONE NEOPLASIE SANGUE ONLUS12
Active, not recruiting
Phase 1
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1Level: LLTClassification code 10028508Term: Mycosis fungoides/Sezary syndromeSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-011020-65-DEEuropean Organisation for Research and Treatment of Cancer30
Active, not recruiting
Phase 1
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.Cutaneous T-cell lymphoma: Mycosis Fungoides, Stage IIB to IV or Sézary SyndromeMedDRA version: 14.1 Level: LLT Classification code 10028508 Term: Mycosis fungoides/Sezary syndrome System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2009-011020-65-GBEuropean Organisation for Research and Treatment of Cancer30